Seneca Therapeutics Announces the Closing of $3.9 million Series B Extension Round

Funding Provides 2+ Years Runway to Complete Phase I/II Trial of Seneca Vally Virus (SVV-001) Currently Underway in High-Grade Neuroendocrine Neoplasms

Read more